A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation
Silvia L. Locatelli,Giuseppa Careddu,Giuliano Giuseppe Stirparo,Luca Castagna,Armando Santoro,Carmelo Carlo-Stella +5 more
TL;DR: Gene expression analysis indicated that the effects of AEZS-136 were associated with the modulation of cell cycle and cell death pathways, and dual PI3K/ERK inhibition might be an effective approach for improving therapeutic outcomes in HL.
Journal ArticleDOI
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.
Robert E. Martell,Igor Puzanov,Wen Wee Ma,Armando Santoro,Grace K. Dy,Laura W. Goff,Gerald J. Fetterly,Shaunita A. Michael,Julie Means-Powell,Feng Chai,Maria Lamar,Matteo Simonelli,Wendy M. Chiang,Jamie Jarboe,Brian Schwartz,Alex A. Adjei +15 more
TL;DR: After a safety review in HCC pts in other studies and a report of febrile neutropenia in this study, the tivantinib dose was reduced to 240 mg BID, and the recommended phase 2 dose (RP2D) of tivaninib plus sorafenib, and antitumor activity was reduced.
Journal ArticleDOI
Tivantinib: a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma
TL;DR: A randomized Phase II study in second-line hepatocellular carcinoma showed statistically significant improvement in time to progression with tivantinib compared to a placebo and overall survival was observed in MET-high patients.
Journal ArticleDOI
High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review
TL;DR: The use of HDCT with autologous HSCT may improve tumor response rates and/or possibly progression-free survival, especially in some selected patient subgroups, but this strategy did not demonstrate in almost all cases to produce significantly higher cure rates than standard-dose chemotherapy.
Journal ArticleDOI
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
Cinzia Pellegrini,Alessandro Broccoli,Alessandro Pulsoni,Luigi Rigacci,Caterina Patti,Guido Gini,Donato Mannina,Monica Tani,Chiara Rusconi,Alessandra Romano,Anna Vanazzi,Barbara Botto,Armando Santoro,Stefan Hoaus,Gian Matteo Rigolin,Pellegrino Musto,Patrizio Mazza,Stefano Molica,Paolo Corradini,Angelo Fama,Francesco Gaudio,Michele Merli,Fioravante Ronconi,Giuseppe Gritti,Daniele Vallisa,Patrizia Tosi,Anna Marina Liberati,Antonello Pinto,Vincenzo Pavone,Filippo Gherlinzoni,Maria Paola Bianchi,Stefano Volpetti,Livio Trentin,Maria Goldaniga,Maurizio Bonfichi,Amalia De Renzo,Corrado Schiavotto,Michele Spina,Angelo Michele Carella,Vittorio Stefoni,Lisa Argnani,Pier Luigi Zinzani +41 more
TL;DR: Activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients are confirmed.